Actively Recruiting
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
Led by Third Affiliated Hospital, Sun Yat-Sen University · Updated on 2025-02-11
234
Participants Needed
1
Research Sites
309 weeks
Total Duration
On this page
Sponsors
T
Third Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor
S
Sun Yat-Sen University Cancer Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). The investigators confirmed that the combination therapy yielded better survival data than the combined administration of Atezolizumab/Bevacizumab and TACE (TACE-AB) in patients with advanced HCC and Type I/II PVTT (Based on Cheng's PVTT classification).
CONDITIONS
Official Title
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between18 and 75 years
- Diagnosis of hepatocellular carcinoma confirmed by radiology, histology, or cytology
- Presence of type I or type II portal vein tumor thrombosis (PVTT)
- Child-Pugh class A liver function
- Eastern Cooperative Group performance status (ECOG) score of 0-1
- No prior systemic therapy for hepatocellular carcinoma
- Adequate blood counts and organ function
- At least one measurable tumor lesion in the liver
You will not qualify if you...
- Diffuse hepatocellular carcinoma
- Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, or mixed hepatocellular/cholangiocarcinoma subtypes
- Evidence of cancer spread outside the liver
- Any condition that prevents TACE or I-125 seeds brachytherapy as assessed by investigators
- History or evidence of significant bleeding or bleeding disorders within 4 weeks before randomization
- Active or past autoimmune disease or immune deficiency
- Untreated or high-risk esophageal or gastric varices for bleeding
- Bleeding from esophageal or gastric varices within 6 months before study treatment
- Significant blood clotting problems
- Pregnant or breastfeeding women
- Serious heart disease
- Severe infections like active tuberculosis
- Serious other medical conditions
- History of organ or cell transplantation
- History of other incurable cancers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Third Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangzhou, China, 510630
Actively Recruiting
Research Team
M
Mingsheng Huang, M.D. & Ph.D.
CONTACT
L
Luwen Mu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here